section name header

Pronunciation

lin-a-KLOE-tide

Classifications

Therapeutic Classification: anti irritable bowel syndrome agents

Pharmacologic Classification: guanylate cyclase-C agonists

Indications

REMS


Action

  • Locally increases levels of cyclic guanosine monophosphate (cGMP); accelerates transit time, increases intestinal fluid and decreases pain sensation.
Therapeutic effects:
  • Increased frequency of bowel movements with decreased pain associated with IBS-C, CIC, or functional constipation.

Pharmacokinetics

Absorption: Minimally absorbed, action is primarily local.

Distribution: Stays within the GI tract with minimal distribution.

Metabolism/Excretion: Converted to its principal active metabolite within the GI tract; subsequently locally degraded to smaller peptides and amino acids; 3–5% found in stool, mostly as the active metabolite.

Half-Life: Unknown.

Time/Action Profile

(improvement in GI symptoms)

ROUTEONSETPEAKDURATION
POunknown6–9 wk1 wk

Following discontinuation.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: diarrhea, abdominal distention, abdominal pain, flatulence, gastrointestinal reflux, vomiting

Neuro: fatigue

Interactions

Drug-drug:

Route/Dosage

Irritable Bowel Syndrome with Constipation

Chronic Idiopathic Constipation

Functional Constipation

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Linzess

Canadian Brand Names

Constella

Code

NDC Code